Vancouver man arrested after driving into Pacific Coliseum entrance during performance, police say
Police said on X, formerly Twitter, that the suspect drove a vehicle into the front entrance of the arena, located at East Vancouver's Hastings Park, during a Cirque du Soleil performance.
Arena security detained the man and police officers took him into custody.
Police said that while it is still early in the investigation, the incident "does not appear to be an act of terrorism."
The suspect, a Vancouver resident, was apprehended under the Mental Health Act, police said.
Police said there are no reported injuries.
B.C. Emergency Health Services said it received a call at 8:02 p.m. regarding a single-vehicle collision at Pacific Coliseum. Three units responded to the scene and paramedics transported one patient.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
39 minutes ago
- National Post
REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
Article content Article content – Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 – Article content Article content TORONTO — Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the Company has entered into a securities purchase agreement (the ' Securities Purchase Agreement ') with High Trail Special Situations LLC (' High Trail '), pursuant to which the Company agreed to sell and issue to High Trail up to US$500,000,000 in aggregate principal amount of unsecured convertible debentures (the ' Convertible Debentures '). The sale and issue of US$50,000,000 principal amount of Convertible Debentures was completed on June 30, 2025 (the ' Private Placement '). The sale and issue of US$450,000,000 of the principal amount of Convertible Debentures will be determined at a future date, upon mutual agreement of the parties. Article content 'This financing represents a major inflection point for Cybin and supports our position as a leader within our sector,' said Doug Drysdale, Chief Executive Officer of Cybin. 'High Trail Capital is an experienced investor, and its confidence and appreciation of our breakthrough clinical data and intellectual property portfolio recognize the potential of the Company. This financing comes at an opportune time for Cybin, as we advance our lead programs, CYB003 and CYB004, in Phase 3 and Phase 2, respectively. CYB003 demonstrated over 70% remission rates and continued durability over 12 months for patients with uncontrolled depression. We await the conclusion of our CYB004 Phase 2 proof-of-concept study, in patients with generalized anxiety disorder,' said Drysdale. Article content Joseph Gunnar & Co., LLC acted as the sole placement agent in connection with this transaction. Article content Pipeline Acceleration Drives Multiple Value Creation Catalysts Article content The funding will accelerate Cybin's clinical-stage programs across multiple high-value indications: Article content CYB003 Program Achievements: Article content Breakthrough Clinical Results: Unprecedented 71% remission rate in major depressive disorder at 12 months after two 16 mg doses in Phase 2 study Durability advantage: 12-month sustained efficacy demonstrating long-term therapeutic benefit FDA Recognition: Breakthrough Therapy Designation received, expediting regulatory pathway Multinational Phase 3 PARADIGM program underway Article content CYB004 Program Momentum: Article content Dual Indication Strategy: Expanding addressable market opportunity Phase 2 GAD study expected to complete around mid-year 2025 1 Article content Commercialization Infrastructure: Article content Value Catalysts Drive Sustained Momentum Article content Near-Term Catalysts: Article content CYB004 Phase 2 GAD study expected to complete around mid-2025 1 Initiation of second CYB003 pivotal study, EMBRACE, around mid-2025 1 EXTEND study initiation imminent 1 Article content Medium-Term Catalysts (2025-2026): Article content Transaction Terms Article content The Convertible Debentures have a two-year term from the closing date (the ' Term '). The Company shall pay guaranteed interest equal to 5.5% of the principal per annum for the Term. Such interest was pre-paid on closing. Upon the occurrence of an event of default, interest shall increase to a rate of 18% per annum on the outstanding principal balance. Pursuant to the terms of the Securities Purchase Agreement, the Company and High Trail may, upon mutual consent, enter into subsequent securities purchase agreements for the purchase and sale of up to an additional US$450,000,000 principal amount of Convertible Debentures, in tranches, in amounts on such dates as may be mutually agreed and each subsequent tranche shall include prepaid interest at a rate of 9.5%. Article content Subject to the terms of the Securities Purchase Agreement and the Convertible Debentures, High Trail will be entitled to convert the principal amount of, and accrued and unpaid interest, if any, on each Convertible Debenture, in whole or in part, from time to time, into common shares in the capital of the Company (the ' Common Shares ') at a conversion price per Common Share equal to the lower of (a) 130% of the volume weighted average price (' VWAP ') of the Common Shares on the day prior to the initial issuance of the Convertible Debentures, or (b) the VWAP of the Common Shares during the five trading days immediately prior to the date of conversion. Article content The Company, in its sole discretion, may prepay any outstanding amount under the Convertible Debentures, in whole or in part, in cash by providing High Trail with advance written notice prior to such prepayment. The prepayment shall include, (i) if paid during the first year after closing, a 5% prepayment premium on the amount of the prepayment or (ii) if paid thereafter, a 3% prepayment premium on the amount of the prepayment. Article content The terms of the Convertible Debentures restrict the conversion of Convertible Debentures by High Trail if such a conversion or exercise would cause High Trail, together with any affiliate thereof, to beneficially own in excess of 4.99% of the number of Common Shares outstanding immediately after giving effect to such conversion. Article content The Company intends to use the net proceeds from the Private Placement for working capital and general corporate purposes. Article content The Convertible Debentures were offered on a private placement basis pursuant to prospectus exemptions in Canada and pursuant to exemptions and exclusions from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws. The Company has agreed to use commercially reasonable efforts to: (a) file a prospectus supplement to the Company's base shelf prospectus dated August 17, 2023, as amended on December 22, 2023, April 8, 2024 and January 6, 2025, with applicable Canadian securities regulators to qualify the secondary market sales of the Common Shares in the United States; and (b) either (i) prepare and file the Canadian prospectus supplement with the United States Securities and Exchange Commission, or (ii) file a prospectus supplement pursuant to General Instruction II.L of Form F-10 with the United States Securities and Exchange Commission to the Company's registration statement on Form F-10 (File No. 333-284173), which was declared effective by the SEC on January 14, 2025, or on such other form as may be available to the Company, in either case qualifying the resale of the Common Shares underlying the Convertible Debentures. Article content No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws Article content About Cybin Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Article content Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Article content There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See 'Cautionary Notes and Forward-Looking Statements'. Article content Cautionary Notes and Forward-Looking Statements Article content Certain statements in this news release constitute forward-looking information and forward-looking statements within the meaning of applicable securities laws (together, 'forward-looking statements'). Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the use of Private Placement proceeds; the conversion of the Convertible Debentures into Common Shares; the sale and issue of US$450,000,000 principal amount of Convertible Debentures at a future date; CYB004 Phase 2 GAD study expected to complete around mid-2025; Initiation of second CYB003 pivotal study, EMBRACE, around mid-2025; the Company's Medium-Term Catalysts for 2025-2026; Phase 3 PARADIGM program enrollment acceleration; the Company's ability to achieve commercial success; and the Company's ability to address the need for new and innovative treatment options for people who suffer from mental health conditions. Article content These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on and with the SEC on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Article content Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Article content Article content Article content Article content Article content Contacts Article content Investor & Media Contact Article content : Article content
CTV News
44 minutes ago
- CTV News
B.C. reports offer ‘road map' for repatriation of Indigenous items, remains
A blessing and reawaken ceremony for the historical repatriation of the Nuxalk Nation totem pole carved by the late Louie Snow after years of effort to release the pole back to the nation from the Royal BC Museum during a ceremony in Victoria, B.C., on Feb. 13, 2023. THE CANADIAN PRESS/Chad Hipolito A pair of reports out of British Columbia are detailing the complex, expensive and under resourced process of repatriating Indigenous historical items or remains back to their homes. The studies, developed in partnership between the First Peoples' Cultural Council and K'yuu Enterprise Corporation, call for changes including the creation of a centralized body to facilitate the work, a repatriation accreditation program for museums and other institutions, and 'substantial' funding and support from the provincial and federal government. Gretchen Fox, an anthropologist and the council's acting heritage manager, said the growing interest in the moral and ethical requirement for repatriation shows resources are needed to set out steps that could be used in B.C. and in other provinces and territories. 'There was a need for a way forward, or a road map — what's involved in repatriation, what's the history of it,' she said. 'To have a really good understanding and documentation of what's been lost, where these ancestors and belongings are held today, and what kind of work specifically is involved in locating them.' Researchers with the K'yuu Enterprise Corporation did a survey and found more than 2,500 B.C. First Nation human remains and upwards of 100,000 belongings are known to be held in 229 institutions — including museums and universities — around the world. Fox said the survey had only a 50 per cent response rate. 'So, we know that the numbers are much higher, and those numbers are just for ancestors and belongings that are associated with B.C. First Nations,' she said. The main report breaks down repatriation into a four-step process starting with planning and research, followed by repatriation itself and the long-term caretaking of the items or remains. It says 60 per cent of B.C. First Nations surveyed have already spent more than $1 million on repatriation work to date. 'Since the Canadian government has yet to commit to dedicated repatriation legislation, policy and funding, many (B.C. First Nations) are reliant on grants and other mechanisms to support their repatriation work,' it says. The report says when applying for grant programs that aren't dedicated to repatriation, nations are forced to focus on strict funding criteria and narrow timelines rather than their own needs. In 2016, B.C. became the first province in Canada to offer a grant to help pay for repatriation. While the report calls that funding 'welcome,' it says the money has not kept pace with requests. It says repatriation in Canada is 'severely underfunded.' 'For decades, B.C. First Nations have funded this work through piecemeal grants and heavy reliance on volunteer labour,' it says. Fox said there are a range of costs, from paying personnel to the technology required to research where items are located or the cost to store them properly. A companion report offers what Fox calls a 'really high level' cost estimate It suggests that if all 204 B.C. First Nations were funded over five years to participate in repatriation at various stages it would cost an estimated $663 million. Fox said the number is not a request for funding, but rather an attempt to test the model and 'show the monumental, significant, costs of this.' The report says repatriation is also an economic and social driver with benefits like health and healing, jobs and community development. 'It has spiritual and cultural impacts of reconnecting with belongings and carrying out responsibilities to ancestors and It's so meaningful, even if it's engaged at a slower pace, or on a smaller scale,' Fox said. She said having a First Nation-led centralized organizing body and programming to facilitate repatriation would be helpful to provide the opportunity to pool experience and resources. 'First Nations in B.C. are really leading the way in repatriation, and quite a few have quite a bit of expertise and experience around doing the work and also insights into the kinds of supports, whether it's legislation (or) policy,' she said. Inviting museums and other holding institutions would also be beneficial, Fox said. In 2023, a totem pole that had been on display at the Royal B.C. Museum, was brought back to Bella Coola, located almost 1,000 kilometres northwest of Vancouver. It was taken in 1913 and became part of the museum's collection. Representatives of the Nuxalk Nation said at the time that they had been trying to get the totem and other artifacts back since 2019. Also in 2023, a memorial totem pole belonging to members of the Nisga'a Nation was returned from the National Museum of Scotland in Edinburgh, where it has been for nearly a century. Last year, the Heiltsuk Nation celebrated the return of a chief's seat that had been in the Royal BC Museum since 1911. Fox said an accreditation program for institutions that hold First Nations' remains and belongings could teach about repatriation and the practices and protocols needed. 'There's not a lot of formal training for folks who are doing the work, so it makes sense for those who are experts to have an arena, to share that,' she said. She said there is still work to be done, but over the last few decades more institutions are recognizing the 'moral and ethical imperative to make things right. That these belongings and ancestors were stolen or taken under duress from First Nations communities, and that the right thing to do is to facilitate their return.' 'At the same time, First Nations repatriation experts are training the next generations within their communities, and they're building relationships with institutions. And so we are seeing some significant movement and recognition that this is the right thing to do,' she said. This report by Ashley Joannou, The Canadian Press, was first published July 1, 2025.
CTV News
an hour ago
- CTV News
OPP takes over Sudbury death investigation
Two off-duty Sudbury police officers have been suspended with pay in connection to the death of 19-year-old Rocco Renaud. Chief Sara Cunningham filed a complaint over their actions on May 23, when officers responded to an unresponsive man in Lively. Renaud later died in hospital. Ontario Provincial Police are now handling the investigation.
